XML 131 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment Information Segment Information

The Company has two operating segments, which constitute the Company’s two reportable segments and the Company’s CEO is the CODM, as defined in ASC Topic 280 - Segment Reporting. Our performance is assessed and resources allocated by the CODM based on the following two reportable segments:

•
Prescription Pharmaceuticals
•
Consumer Health

The Company’s Prescription Pharmaceuticals segment principally consists of generic and branded prescription pharmaceuticals products which span a broad range of indications as well as a variety of dosage forms including: sterile ophthalmics, injectables and inhalants, and non-sterile oral liquids, topicals and nasal sprays. The Company’s Consumer Health segment principally consists of animal health and over-the-counter (“OTC”) products, both branded and private-label.  OTC products include, but are not limited to, a suite of products for the treatment of dry eye sold under the TheraTears® brand name.

Financial information about the Company’s reportable segments is based upon internal financial reports that aggregate certain operating information. The Company’s CODM oversees operational assessments and resource allocations based upon the results of the Company’s reportable segments, which have available and discrete financial information.

Selected financial information by reportable segment is presented below (in thousands):
 
Years ended December 31,
 
2019
 
2018
 
2017
REVENUES, NET:
 
 
 
 
 
Prescription Pharmaceuticals
$
604,212

 
$
620,669

 
$
772,524

Consumer Health
78,217

 
73,349

 
68,521

Total revenues, net
$
682,429

 
$
694,018

 
$
841,045

GROSS PROFIT:
 

 
 

 
 

Prescription Pharmaceuticals
$
217,767

 
$
213,560

 
$
402,082

Consumer Health
34,939

 
32,456

 
30,124

Total gross profit
$
252,706

 
$
246,016

 
$
432,206



The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. Inter-segment activity at the gross profit level is minimal. The Company does not have discrete assets by segment, as certain manufacturing and warehouse facilities support more than one segment, and therefore does not report assets by segment. Financial information including revenues and gross profit by product or product line is not provided, as to do so would be impracticable.

During the years ended December 31, 2019, 2018 and 2017, approximately $13.2 million, $16.4 million and $25.5 million of the Company’s net revenue, respectively, was from customers located in foreign countries. All of the net revenue was related to our Prescription Pharmaceutical segment.

The carrying amounts of Goodwill by segment were as follows (in thousands):
 
Prescription Pharmaceuticals
 
Consumer Health
 
Total
December 31, 2017
$
268,593

 
$
16,717

 
$
285,310

Acquisitions and other adjustments
—

 
—

 
—

Impairments
—

 
—

 
—

Dispositions
—

 
—

 
—

Foreign currency translations
(1,431
)
 
—

 
(1,431
)
December 31, 2018
$
267,162

 
$
16,717

 
$
283,879

Acquisitions and other adjustments
—

 
—

 
—

Impairments
(15,955
)
 
—

 
(15,955
)
Dispositions
—

 
—

 
—

Foreign currency translations
(1
)
 
—

 
(1
)
December 31, 2019
$
251,206

 
$
16,717

 
$
267,923